Apyx Medical Corporation filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 5, 2026, reporting third-quarter net sales of $14.030 million and a net loss attributable to stockholders of $1.785 million.

Key Highlights

  • Net sales: $14.030 million for the three months ended September 30, 2026, compared with $12.877 million in the same period of 2025, according to the filing.
  • Net loss attributable to stockholders: $1.785 million, or $0.04 per basic and diluted share, for Q3 2026, versus $1.984 million, or $0.05 per share, in Q3 2025.
  • Nine-month net sales: $40.404 million for the nine months ended September 30, 2026, compared with $33.680 million in the same period of 2025.
  • Accumulated deficit: $96.258 million as of September 30, 2026, up from $89.122 million at December 31, 2025.
  • Cash and cash equivalents: $25.777 million at September 30, 2026, down from $31.740 million at December 31, 2025.
  • Total equity: $10.037 million at September 30, 2026, compared with $14.831 million at December 31, 2025.
  • Shares outstanding: 42,124,023 shares of common stock as of November 4, 2026, per the filing.

Apyx Medical Reports Improved Q3 Revenue Amid Continued Operating Losses

According to the filing, Apyx Medical Corporation (NASDAQ:APYX) reported net sales of $14.030 million for the three months ended September 30, 2026, an increase from $12.877 million in the comparable prior-year quarter. Gross profit for the third quarter was $9.001 million, compared with $8.297 million in Q3 2025. Total other costs and expenses were $9.572 million for the quarter, resulting in a loss from operations of $571,000, an improvement from the $832,000 operating loss reported in Q3 2025.

For the nine months ended September 30, 2026, the company disclosed net sales of $40.404 million, up from $33.680 million in the first nine months of 2025. The nine-month loss from operations was $3.288 million, compared with a $6.457 million operating loss in the year-earlier period. Net loss for the nine-month period was $7.021 million, versus $9.865 million in the same period of 2025. Interest expense for the nine months was $4.177 million in 2026, compared with $4.182 million in 2025, reflecting long-term debt reported at $35.573 million, net of debt discounts and issuance costs, as of September 30, 2026.

The condensed consolidated balance sheet showed total assets of $61.670 million as of September 30, 2026, versus $66.840 million at December 31, 2025. Inventories increased to $11.950 million from $8.602 million over the same period. Stock-based compensation for the nine months ended September 30, 2026 was $2.139 million, the filing stated. As of September 30, 2026, the company had 42,124,023 shares of $0.001 par value common stock issued and outstanding, with 10,000,000 preferred shares authorized and none issued.

What Was Disclosed

Apyx Medical filed its unaudited quarterly report covering the period ended September 30, 2026, disclosing revenue growth in both the three- and nine-month periods compared with 2025, alongside a reduced net loss, an accumulated deficit of $96.258 million, and cash of $25.777 million.